|
[1]
|
Anonymous (1999) Hepatitis C-Global Prevalence (Update). World Health Organization Weekly Epidemiological Record, 74, 425-427.
|
|
[2]
|
McHutchison, J.G., Goodman, Z.D., Ling, M.H., et al. (1998) Interferon Alfa-2b Alone or in Combination with Ribavirin as Initial Treatment for Chronic Hepatitis C. Hepatitis Interventional Therapy Group. The New England Journal of Medicine, 339, 1485-1492.
http://dx.doi.org/10.1056/NEJM199811193392101
|
|
[3]
|
Youngster, S., Wang, Y.S., Grace, M., et al. (2002) Structure, Biology and Therapeutic Implications of Pegylated Interferon Alpha-2b. Current Pharmaceutical Design, 8, 2139-2157.
http://dx.doi.org/10.2174/1381612023393242
|
|
[4]
|
Fried, M.W., Shiffman, M.L., Reddy, K.R., et al. (2002) Peginterferon Alfa-2a plus Ribavirin for Chronic Hepatitis C Virus Infection. The New England Journal of Medicine, 347, 975-982.
http://dx.doi.org/10.1056/NEJMoa020047
|
|
[5]
|
McHutchison, J.G., Manns, M., Patel, K., et al. (2002) Adherence to Combination Therapy Enhances Sustained Response in Genotype-1-Infected Patients with Chronic Hepatitis C. Gastroenterology, 123, 1061-1069.
http://dx.doi.org/10.1053/gast.2002.35950
|
|
[6]
|
Kamal, S.M., EI Kamary, S.S., Shardel, M.D., et al. (2007) Pegylated Interferon Alpha-2b plus Ribavirin in Patients with Genotype 4 Chronic Hepatitis C: The Role of Rapid and Early Virologic Response. Hepatology, 46, 1732-1740.
http://dx.doi.org/10.1002/hep.21917
|
|
[7]
|
Di Bisceglie, A.M. and Hoofnagle, J.H. (2002) Optimal Therapy of Hepatitis C. Hepatology, 36, S121-127.
http://dx.doi.org/10.1002/hep.1840360716
|
|
[8]
|
Hayashi, P.H., Mehia, C., Joachim Reimers, H., et al. (2006) Splenectomy for Thrombocytopenia in Patients with Hepatitis C Cirrhosis. Journal of Clinical Gastroenterology, 40, 740-744.
http://dx.doi.org/10.1097/00004836-200609000-00015
|
|
[9]
|
Renault, P.F. and Hoofnagle, J.H. (1989) Side Effects of Alpha Interferon. Seminars in Liver Disease, 9, 273-277.
http://dx.doi.org/10.1055/s-2008-1040523
|
|
[10]
|
Martin, T.G. and Shuman, M.A. (1998) Interferon-Induced Thrombocytopenia; It Is Time for Thrombopoietin. Hepatology, 28, 1430-1432.
http://dx.doi.org/10.1002/hep.510280536
|
|
[11]
|
Maddison, F.E. (1973) Embolic Therapy of Hypersplenism. Investigative Radiology, 8, 280-281.
http://dx.doi.org/10.1097/00004424-197307000-00054
|
|
[12]
|
Moges, M.F., Spigos, D.G., Pollak, R., Abejo, R., Pavel, D.G., Tan, W.S. and Jonasson, O. (1984) Partial Splenic Embolization, an Alternative to Splenectomy—Results of a Prospective, Randomized Study. Surgery, 96, 694-702.
|
|
[13]
|
Pålsson, B. and Verbaan, H. (2005) Partial Splenic Embolization as Pretreatment for Antiviral Therapy in Hepatitis C Virus Infection. European Journal of Gastroenterology & Hepatology, 17, 1157-1164.
|
|
[14]
|
Kercher, K.W., Carbonell, A.M., Heniford, B.T., Matthews, B.D., Cunningham, D.M. and Reindollar, R.W. (2004) Laparoscopic Splenectomy Reverses Thrombocytopenia in Patients with Hepatitis C Cirrhosis and Portal Hypertension. Journal of Gastrointestinal Surgery, 8, 120-126.
http://dx.doi.org/10.1016/j.gassur.2003.10.009
|
|
[15]
|
King, H., Shumacker Jr., H.B. (1952) Splenic Studies: I. Susceptibility to Infection after Splenectomy Performed Infancy. Annals of Surgery, 136, 239-242.
http://dx.doi.org/10.1097/00000658-195208000-00006
|
|
[16]
|
Evans, D.I. (1985) Postsplenectomy Sepsis 10 Years or More after Operation. Journal of Clinical Pathology, 38, 309-311.
http://dx.doi.org/10.1136/jcp.38.3.309
|
|
[17]
|
Cullingford, G.L., Watkins, D.N., Watts, A.D. and Mallon, D.F. (1991) Severe Late Postsplenectomy Infection. British Journal of Surgery, 78, 716-721.
http://dx.doi.org/10.1002/bjs.1800780626
|
|
[18]
|
Jockovich, M., Mendenhall, N.P., Somebeck, M.D., Talbert, J.L., Copeland III, E.M. and Bland, K.I. (1994) Long-Term Complications of Laparotomy in Hodgkin’s Disease. Annals of Surgery, 219, 615-621.
http://dx.doi.org/10.1097/00000658-199406000-00004
|
|
[19]
|
Landgren, O., Bjorkholm, M., konradsen, H.B., Söderqvist, M., Nilsson, B. and Gustavsson, A. (2004) A Prospective Study on Antibody Response to Repeated Vaccinations with Pneumococcal Capsular Polysaccharide in Splentomized Individuals with Special Reference to Hodgkin’s Lymphoma. Journal of Internal Medicine, 255, 664-673.
http://dx.doi.org/10.1111/j.1365-2796.2004.01312.x
|
|
[20]
|
Shatz, D.V. (2005) Vaccination Considerations in the Asplenic Patient. Expert Review of Vaccines, 4, 27-34.
http://dx.doi.org/10.1586/14760584.4.1.27
|
|
[21]
|
White, K.S., Covington, D., Churchill, P., Maxwell, J.G., Norman, K.S. and Clancy, T.V. (1991) Patient Awareness of Health Precautions after Splenectomy. American Journal of Infection Control, 19, 36-41.
http://dx.doi.org/10.1016/0196-6553(91)90158-9
|